Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/76
Title: Pharmacological treatment of cognitive deficits in Alzheimer's disease.
Authors: Brodaty, Henry
Ames, David J.
Boundy, K.
Snowden, John A.
Storey, E.
Yates, Mark
Issue Date: 2001
Publisher: Australasian Medical Publishing Co.
Place of publication: Pyrmont, NSW.
Publication Title: Journal of the Australian Medical Association
Volume: 175
Issue: 6
Start Page: 324
End Page: 329
Abstract: Clinical trials and independent reviews support the use of cholinesterase inhibitors for treating the symptoms of patients with mild to moderate Alzheimer's disease (AD). Before initiating cholinesterase inhibitor therapy, patients should be thoroughly assessed, and the diagnosis confirmed, preferably by a specialist. Compliance with cholinesterase inhibitor therapy should be monitored and the response (in global, cognitive, functional and behavioural domains) reassessed after 2-3 months of treatment. Vitamin E may be protective against AD, and therapy with 1000 IU twice daily may be considered. There is insufficient evidence to support the use of other antioxidant agents, anti-inflammatory agents, monoamine oxidase B inhibitors, folate/homocysteine or antihypertensive drugs in patients with AD, or hormone replacement therapy in affected women.
URI: http://hdl.handle.net/11054/76
ISSN: 0025-729X
Internal ID Number: 00062
Health Subject: REVIEW
ALZHEIMER DISEASE - DRUG THERAPY
CHOLINESTERASE INHIBITORS - THERAPEUTIC USE
HUMANS
PRACTICE GUIDELINES AS TOPIC
UNITED STATES
UNITED STATES FOOD AND DRUG ADMINISTRATION
CHOLINESTERASE INHIBITORS
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
File Description SizeFormat 
00062.pdfCopyright 2001. Reproduced with permission.3.06 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.